Skeletal muscle-derived cell implantation for the treatment of fecal incontinence: a multicenter, randomized, double-blind, placebo controlled, parallel-group, dose-finding clinical study

Trial Profile

Skeletal muscle-derived cell implantation for the treatment of fecal incontinence: a multicenter, randomized, double-blind, placebo controlled, parallel-group, dose-finding clinical study

Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Aug 2017

At a glance

  • Drugs ICEF 15 (Primary)
  • Indications Faecal incontinence
  • Focus Therapeutic Use
  • Acronyms STEFFI
  • Sponsors Innovacell Biotechnologie GmbH
  • Most Recent Events

    • 16 Aug 2017 This study has been discontinued in Slovenia (end date: 2017-08-04) as per European Clinical Trials Database.
    • 11 Aug 2017 This study has been discontinued in Germany as per European Clinical Trials Database.
    • 21 Apr 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top